Abstract
9013 Background: BCC pathogenesis involves abnormal Hedgehog pathway (HP) signaling. In the ERIVANCE BCC trial, vismodegib (VISMO), the first FDA-approved HP inhibitor (HPI), showed objective respo...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
